Patients treated with lecanemab experience delayed progression to moderate and severe Alzheimer's disease, enhancing quality of life.
The modelling indicates that lecanemab leads to additional life-years and decreases time spent in institutional care across various patient scenarios.
Health outcomes were estimated using advanced modelling techniques, focusing on the effects of early treatment initiation.
Further validation may support broader use of lecanemab in clinical practice to benefit patients with early Alzheimer's disease.
Abstract
Patients treated with lecanemab experience delayed progression to Moderate and Severe AD, resulting in additional life-years (LYs) and reduced time in institutional care.